Zacks: Analysts Anticipate Scpharmaceuticals Inc (SCPH) to Post -$0.59 Earnings Per Share
Brokerages expect Scpharmaceuticals Inc (NASDAQ:SCPH) to post ($0.59) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Scpharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.61) and the highest estimate coming in at ($0.57). Scpharmaceuticals reported earnings of ($0.47) per share during the same quarter last year, which indicates a negative year over year growth rate of 25.5%. The company is expected to issue its next quarterly earnings report on Monday, May 6th.
According to Zacks, analysts expect that Scpharmaceuticals will report full-year earnings of ($2.07) per share for the current year, with EPS estimates ranging from ($2.23) to ($1.91). For the next year, analysts expect that the company will report earnings of ($1.39) per share, with EPS estimates ranging from ($1.46) to ($1.32). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Scpharmaceuticals.
Scpharmaceuticals (NASDAQ:SCPH) last issued its earnings results on Thursday, March 21st. The company reported ($0.27) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.17.
Shares of NASDAQ:SCPH opened at $3.06 on Tuesday. The company has a market cap of $46.08 million, a PE ratio of -1.92 and a beta of 1.18. Scpharmaceuticals has a one year low of $2.44 and a one year high of $15.70. The company has a debt-to-equity ratio of 0.10, a quick ratio of 13.77 and a current ratio of 13.77.
In other Scpharmaceuticals news, major shareholder Ra Capital Healthcare Fund Lp acquired 389,862 shares of the company’s stock in a transaction dated Thursday, April 11th. The shares were purchased at an average cost of $2.70 per share, for a total transaction of $1,052,627.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.80% of the stock is currently owned by company insiders.
A hedge fund recently raised its stake in Scpharmaceuticals stock. JPMorgan Chase & Co. raised its position in Scpharmaceuticals Inc (NASDAQ:SCPH) by 1,268.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,664 shares of the company’s stock after acquiring an additional 21,008 shares during the period. JPMorgan Chase & Co. owned approximately 0.12% of Scpharmaceuticals worth $133,000 as of its most recent filing with the Securities & Exchange Commission. 42.24% of the stock is currently owned by institutional investors.
scPharmaceuticals Inc, a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting.
Recommended Story: Investing in Blue-Chip Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.